StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Biogen's ebitda for the twelve months ending Mar 31, 2022 was $3.01B, down 27.5% year over year. For fiscal 2021 it was $3.33B, down 33.5% from the year before. Over ten years it grew 4.8% a year on average. The highest annual figure on record is $7.51B in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2021Dec 31, 2021$3.33B-33.5%
FY2020Dec 31, 2020$5.01B-33.3%
FY2019Dec 31, 2019$7.51B+14.8%
FY2018Dec 31, 2018$6.54B+1.7%
FY2017Dec 31, 2017$6.43B+10.2%
FY2016Dec 31, 2016$5.83B+6.2%
FY2015Dec 31, 2015$5.49B+17.8%
FY2014Dec 31, 2014$4.66B+52.9%
FY2013Dec 31, 2013$3.05B+37.2%
FY2012Dec 31, 2012$2.22B+6.6%
FY2011Dec 31, 2011$2.08B+29.9%
FY2010Dec 31, 2010$1.60B-6.9%
FY2009Dec 31, 2009$1.72B+2.8%
FY2008Dec 31, 2008$1.68B+44.4%
FY2007Dec 31, 2007$1.16B–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2022Mar 31, 2022$753.80M-30.0%
Q4 FY2021Dec 31, 2021$721.80M–
Q3 FY2021Sep 30, 2021$927.20M-22.8%
Q2 FY2021Jun 30, 2021$602.90M-71.1%
Q1 FY2021Mar 31, 2021$1.08B-44.5%
Q4 FY2020Dec 31, 2020-$220.90M-113.2%
Q3 FY2020Sep 30, 2020$1.20B-43.8%
Q2 FY2020Jun 30, 2020$2.09B+0.7%
Q1 FY2020Mar 31, 2020$1.94B+19.5%
Q4 FY2019Dec 31, 2019$1.67B+19.1%
Q3 FY2019Sep 30, 2019$2.14B+4.5%
Q2 FY2019Jun 30, 2019$2.07B+49.7%
Q1 FY2019Mar 31, 2019$1.62B-4.7%
Q4 FY2018Dec 31, 2018$1.41B-16.0%
Q3 FY2018Sep 30, 2018$2.04B+11.6%
Q2 FY2018Jun 30, 2018$1.38B+0.1%
Q1 FY2018Mar 31, 2018$1.70B+10.9%
Q4 FY2017Dec 31, 2017$1.68B+57.3%
Q3 FY2017Sep 30, 2017$1.83B–
Q2 FY2017Jun 30, 2017$1.38B–
Q1 FY2017Mar 31, 2017$1.54B–
Q4 FY2016Dec 31, 2016$1.06B–

More Biogen figures

See a number that looks wrong?